2017-000161-75: ICON9 is a research study investigating patients with recurrent ovarian, fallopian tube or primary peritoneal cancer, who have had their tumour shrunk by chemotherapy. The study will address whether such patients may benefit from maintenance treatment with two new anti-cancer, orally-administrated drugs called olaparib and cediranib. |
|
|
| Not yet recruiting | 3 | 618 | Europe | Olaparib, Cediranib, AZD2171 Maleate, Film-coated tablet, Lynparza | University College London, Cancer Research UK, AstraZeneca UK Limited | High grade serous or endometrioid ovarian, fallopian and peritoneal cancer, Ovarian, fallopian and peritoneal cancer, Diseases [C] - Cancer [C04] | | | | |
2019-004914-32: Identification of lymphatic metastasis in patients with oral cancer by means of sentinel lymph node biopsy using Gallium-68-Tilmanocept PET-CT Identificatie van lymfekliermetastasen bij patiënten met mondholtekanker middels de schildwachtklierprocedure met behulp van Gallium-68-Tilmanocept PET-CT |
|
|
| Not yet recruiting | 3 | 94 | Europe | Gallium-68-Tilmanocept, V09IA009, Injection | University Medical Center Utrecht, University Medical Center Utrecht | The IMP will be used for the identification of sentinel lymph nodes in patients with early-stage oral squamous cell carcinoma and a clinically negative neck (T1-3N0M0). Het IMP zal worden gebruikt voor identificatie van schildwachtklieren bij patiënten met vroeg-stadium mondholte plaveiselcelcarcinomen (T1-3N0M0)., The IMP will be used to identify lymph nodes which are most likely to harbor metastasis in patients with early stage oral cavity cancer. Het IMP zal worden gebruikt om lymfeklieren te identificeren die het hoogste risico hebben op het bevatten van eventuele metastasen bij patiënten met vroeg-stadium mondholtekanker., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] | | | | |
NEOPCOSCC, NCT05798793: Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 309 | RoW | Camrelizumab plus TP, SHR-1210 plus Docetaxel, Cisplatin, TP, Docetaxel, Cisplatin | Hospital of Stomatology, Wuhan University, Jiangsu HengRui Medicine Co., Ltd. | Oral Squamous Cell Carcinoma | 07/26 | 10/26 | | |
